Expert Interview
Discussing current uptake for Regeneron's Eylea (aflibercept) HD uptake and Roche Vabysmo
Ticker(s): REGN, RHHBYInstitution: Rush University & Illinois Retina Associates
- Assistant Professor of Ophthalmology at Rush University Medical Center & co-investigator on several clinical trials.
- Manages 20 patints a week with wAMD.
- Research interests include assessing the color performance of the NGENUITY 3D visualization system and meta-analyses of cytokines in various retinal diseases; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula.
Roughly how many patients do you manage with wet amd?
Added By: wilson_adminHow many are on Eylea?
Added By: wilson_adminHow will the J code impact your prescribing patterns?
Added By: wilson_adminHow do you approach the use of Avastin versus Eylea as a first-line treatment for wet AMD, and what influences the decision to switch between these or other medications?
What factors determine the choice between Lucentis biosimilars and other treatment options, and how do insurance policies impact these decisions?
What is your experience with extending dosing intervals for Eylea HD and Vabysmo, and how common is it to achieve 12- or 16-week dosing frequencies in practice?
How do you evaluate the potential of gene therapies and TKI inhibitors in wet AMD treatment, particularly in comparison to existing VEGF therapies?
What trends do you observe in the uptake of newer treatments like Vabysmo and Eylea HD, and how do you anticipate their future impact on clinical practice and market share?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
